An interventional study of Accompanying caregivers by paramedical team in Head and Neck Cancer, sponsored by Centre Henri Becquerel. Active, not recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 236 studies in Head and Neck Neoplasms with a site in France — 49 open to participants now, 69 under way, 11 of them phase 3. Head and Neck Neoplasms · France.
Among the 236 studies in Head and Neck Neoplasms with a site in France, this one is the 142nd largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2022, is one of 63 with no phase, reaches primary completion later than 19 of the 68 other live ones, and was the 191st registered.
2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.
Browse Head and Neck Neoplasms studies →49 of the 236 studies in Head and Neck Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Henri Becquerel · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Groupe Oncologie Radiotherapie Tete et Cou · Sites in France
Ages 18–80
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
UNICANCER · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
236 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 75 · Phase 3 44 · Phase 4 5
First in 1994; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is close to the median of 46 across 2,036 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 110 across the 197 interventional studies, 121 across the 38 observational. Of the 148 that completed or were terminated, 38 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 236 have an industry lead sponsor. The 10 most frequent:
Centre Henri Becquerel is the lead sponsor of 59 studies on the registry; 17 are open to participants now.
Centre Henri Becquerel has 6 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
14 of the studies in Head and Neck Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06910566Centre Oscar LambretFactors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy | 2026-11 |
| NCT04842162Gustave Roussy, Cancer Campus, Grand ParisStudy Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery | 2026-11 |
| NCT05874492Association Francaise pour la Recherche ThermaleEvaluation of the Medical Benefit of Spa Therapy on Fibrosis After Radiotherapy for Breast Cancer or UADT (Upper Aerodigestive Tract) Cancer | 2026-12 |
| NCT05091190Hospices Civils de LyonImmunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers | 2026-12-11 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
Add all 14 to your calendar (.ics) → With an account.
Among the 236 studies in Head and Neck Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Head and Neck invasive cancer usually requires surgery that is associated with modifications of the body structure of patient regarding breathing, eating and communication. These modifications are correlated with an important loss of autonomy in patients. During the study, while the patient is hospitalised after the surgery, the paramedical team will train the caregiver of the patient from experimental group a new dimension of autonomy in order to assure a safe return home. The level of learning depends on each caregiver and patient; therefore, an adapted training is provided.
This study evaluates the impact of paramedical care in accompanying caregivers of patients that had surgery for an ENT invasive cancer, by comparing the experimental group (paramedical care) to the standard group (standard care).
The hypothesis of the study is that a benefit will be seen in the experimental group, by reducing the caregiver burden, improving the quality of life of patients and lowering the rate of hospitalisations and prolonged hospitalisations in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Accompanying caregivers by paramedical team
At each study visit (baseline, one week after hospital discharge, 4-8 weeks after surgery, 8-12 weeks after surgery and 16-20 weeks after surgery), the paramedical team have a dedicated meeting with the caregiver of the patient (at hospital or remote) and teach them the care procedures needed in accompanying the patient and the evaluate the learning progress. The training is adapted to each caregiver, according to his/her motivation and his/her ability. The goal is to have the training regarding the enteral nutrition, prevention of dehydration, pain management.
Comparison of the impact of paramedical care on the caregiving burden between the two groups
Via Zarit Burden Interview
Time frame: At 20 weeks after surgery
Comparison of the impact of paramedical care on the caregiving burden between the two groups
Via Zarit Burden Interview
Time frame: At 8 weeks after surgery
Comparison of the impact of paramedical care on the caregiving burden between the two groups
Via Zarit Burden Interview
Time frame: At 12 weeks after surgery
Measure of quality of life in the two groups
WHOQOL-26
Time frame: baseline
Measure of quality of life in the two groups
QLQ-H\&N35
Time frame: baseline
Measure of quality of life in the two groups
QLQ-H\&N35
Time frame: one week after hospital discharge
Measure of quality of life in the two groups
WHOQOL-26
Time frame: one week after hospital discharge
Measure of quality of life in the two groups
QLQ-H\&N35
Time frame: between 4 and 8 weeks after surgery
Measure of quality of life in the two groups
WHOQOL-26
Time frame: between 8 and 12 weeks after surgery
Measure of quality of life in the two groups
WHOQOL-26
Time frame: between 16 and 20 weeks after surgery
Measure of quality of life in the two groups
Via QLQ-H\&N35
Time frame: between 16 and 20 weeks after surgery
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2022 to primary completion in Oct 2026, 47 months.
Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 47 months is above that.
Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Henri Becquerel